<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261131</url>
  </required_header>
  <id_info>
    <org_study_id>9199</org_study_id>
    <nct_id>NCT00261131</nct_id>
  </id_info>
  <brief_title>Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy</brief_title>
  <official_title>Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy: A Double-Blind, Randomized, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <brief_summary>
    <textblock>
      The study proposes to determine if injections of BTX-A to the hamstring muscles result in&#xD;
      measurable physiologic changes not observed with normal saline injections in children with&#xD;
      spastic diplegic cerebral palsy who walk with a flexed-knee gait pattern.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study proposes to: (1) to determine if injections of BTX-A to the hamstring muscles&#xD;
      result in measurable physiologic (body structure and body function) changes not observed with&#xD;
      normal saline injections, in children with spastic diplegic CP who walk with a flexed-knee&#xD;
      gait pattern; (2) to assess whether physiologic changes translate into functional (activity&#xD;
      and participation) improvements; (3) to evaluate family's perception of change in function,&#xD;
      activity, participation, and quality of life.&#xD;
&#xD;
      This study will demonstrate if BTX-A injected into overactive hamstring muscles of children&#xD;
      with spastic cerebral palsy (CP) and a flexed-knee walking pattern has measurable effects&#xD;
      across the spectrum of dimensions of disablement of the International Classification of&#xD;
      Functioning, Disability, and Health (ICF). It is a multi-center, prospective, randomized,&#xD;
      double-blind trial comparing results of injection of BTX- A and placebo saline in controls,&#xD;
      into overactive hamstring muscles, using multiple outcomes measures. Temporal-spatial gait&#xD;
      parameters, instrumented 3DGA kinematics, passive ROM, spasticity measurement with both&#xD;
      Ashworth and Tardieu scales, muscle strength/control, Gross Motor Function Measurement&#xD;
      (GMFM), Pediatric Outcomes Data Collection Instrument (PODCI), Gillette Functional Assessment&#xD;
      Questionnaire (FAQ), 6-Minute Walk Test, and Goal Attainment Scale (GAS), assessing all ICF&#xD;
      domains, will be collected at baseline and at 1 month, 3 months, and 6 months post-injection.&#xD;
      Power analysis demonstrates the need to randomize 250 children (125 with BTX-A, 125 with&#xD;
      saline), allowing for attrition. Nine participating hospitals will contribute patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3DGA Kinematics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Passive Range of Motion</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Spasticity Measurement with AShworth and Tardieu Scales</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle Strength and Control</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gross Motor Function Measurement (GMFM)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Outcomes Data Collection Instrument (PODCI)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gillette Functional Assessment Questionnaire (GFAQ)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-Minute Walk Test</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goal Attainment Scale (GAS)</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Spastic Diplegic Cerebral Palsy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin A</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Spastic cerebral palsy;&#xD;
&#xD;
          2. Bilateral lower extremity involvement;&#xD;
&#xD;
          3. Spasticity present in the hamstrings;&#xD;
&#xD;
          4. Flexed knee gait &gt;15 degrees by observation (OGS);&#xD;
&#xD;
          5. Age between 3 and 18 years old; (&#xD;
&#xD;
          6. GMFCS Level I to Level IV; (&#xD;
&#xD;
          7. Able to walk a minimum of 4 complete steps without resting with and without&#xD;
             braces/shoes a minimum of 3 times;&#xD;
&#xD;
          8. Able to follow simple commands;&#xD;
&#xD;
          9. Cooperative with physicians and therapist;&#xD;
&#xD;
         10. Able to tolerate application of equipment to the skin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Rhizotomy surgery within the last 1 year;&#xD;
&#xD;
          2. Lower extremity surgical procedures (soft tissue or bony) within the past 1 year;&#xD;
&#xD;
          3. Currently implanted and operating Intrathecal Baclofen Pump (oral baclofen OK);&#xD;
&#xD;
          4. Lower extremity BTX-A injections within the past 6 months;&#xD;
&#xD;
          5. Multilevel BTX-A injections;&#xD;
&#xD;
          6. Gait trainer reliance;&#xD;
&#xD;
          7. Serial casting 3 months prior to or during study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip E. Gates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospitals for Children</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>November 30, 2005</study_first_submitted>
  <study_first_submitted_qc>November 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2005</study_first_posted>
  <last_update_submitted>February 4, 2009</last_update_submitted>
  <last_update_submitted_qc>February 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2009</last_update_posted>
  <keyword>cerebral palsy</keyword>
  <keyword>spasticity</keyword>
  <keyword>diplegia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

